These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2904713)

  • 1. Analytical problems encountered during high-performance liquid chromatographic separation and coulometric detection of bopindolol metabolites in human plasma.
    Perkins SL; Tattrie B; Johnson PM; Rabin EZ
    Ther Drug Monit; 1988; 10(4):480-5. PubMed ID: 2904713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Column liquid chromatographic determination of hydrolysed bopindolol, in the picogram per millilitre range in plasma, using cartridge extraction and dual electrochemical detection.
    Humbert H; Denouel J; Keller HP
    J Chromatogr; 1987 Nov; 422():205-15. PubMed ID: 2893803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers.
    Dayer P; Mérier G; Perrenoud JJ; Marmy A; Leemann T
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S20-4. PubMed ID: 2439813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of bopindolol and its active metabolite 18-502 in human plasma by high-performance liquid chromatography.
    Oddie CJ; Jackman GP; Bobik A
    J Chromatogr; 1983 Apr; 273(2):469-74. PubMed ID: 6863461
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
    Aellig WH; Nüesch E; Engel G; Grevel J; Niederberger W; Rosenthaler J
    Br J Clin Pharmacol; 1986 Jan; 21(1):45-51. PubMed ID: 2868747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of bopindolol by sequential injection technique with spectrophotometric detection.
    Satínský D; Sklenárová H; Huclová J; Karlícek R
    Farmaco; 2003 Oct; 58(10):1057-62. PubMed ID: 14505739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.
    Wensing G; Branch RA; Humbert H; Ohnhaus EE; Kirch W
    Eur J Clin Pharmacol; 1990; 39(6):569-72. PubMed ID: 1982762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
    Aellig WH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S12-5. PubMed ID: 2439811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bopindolol: a slowly dissociating antagonist from the beta-adrenoceptors in guinea pig atria.
    Hosohata Y; Hattori K; Shen Y; Okuyama M; Kaneko H; Ohnuki T; Suzuki J; Nagatomo T
    Pharmacology; 1998 Oct; 57(4):180-7. PubMed ID: 9730775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatography of deacetylmetipranolol in plasma.
    Tkaczyková M; Safarík L
    J Pharm Biomed Anal; 1989; 7(12):1805-10. PubMed ID: 2577449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Certain beta-blockers can decrease beta-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol.
    De Blasi A; Fratelli M; Marasco O
    Circ Res; 1988 Aug; 63(2):273-8. PubMed ID: 2899461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.
    MacDonald NJ; Grant AC; Rodger RS; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1991 Jun; 31(6):697-700. PubMed ID: 1678272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.
    Dayer P; Leemann T; Marmy A; Rosenthaler J
    Eur J Clin Pharmacol; 1985; 28(2):149-53. PubMed ID: 2859203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers.
    Hosohata Y; Sasaki K; Shen Y; Hattori K; Suzuki J; Nagatomo T
    Biol Pharm Bull; 1995 Aug; 18(8):1066-71. PubMed ID: 8535397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous modeling of bopindolol kinetics and dynamics.
    Platzer R; Galeazzi RL; Niederberger W; Rosenthaler J
    Clin Pharmacol Ther; 1984 Jul; 36(1):5-13. PubMed ID: 6329585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma lipid fractions during bopindolol treatment in hypertensive patients.
    van Brummelen P; Bolli P; Koolen MI; Staehelin HB; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S42-4. PubMed ID: 2439818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective extraction of beta-blockers from biological fluids by column-switching high-performance liquid chromatography using an internal-surface phenylboronic acid precolumn.
    Ohta T; Niida S; Nakamura H
    J Chromatogr B Biomed Appl; 1996 Jan; 675(1):168-73. PubMed ID: 8634760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
    Grevel J
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High performance liquid chromatographic determination of the enantiomers of beta-adrenoceptor blocking agents in biological fluids. I: Studies with pindolol.
    Hsyu PH; Giacomini KM
    J Pharm Sci; 1986 Jun; 75(6):601-5. PubMed ID: 2874209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypotensive effect of bopindolol in pithed rats.
    Tanaka H; Takahashi S; Shigenobu K
    Gen Pharmacol; 1993 Mar; 24(2):373-5. PubMed ID: 8097742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.